Verification Opinion
Zhongtian Guofu Securities Co., Ltd. (hereinafter referred to as "Zhongtian Guofu Securities" or "the Sponsor") is the sponsor for Meikang Biotechnology Co., Ltd. (hereinafter referred to as "Meikang Biotechnology" or "the Company") during the continuous supervision phase of its stock issuance to specific targets. In accordance with relevant regulations, including the "Administrative Measures for the Sponsorship of Securities Issuance and Listing," the "Regulations on the Supervision of Raised Funds by Listed Companies," and others, we conducted a prudent verification of Meikang Biotechnology's use of part of its idle raised funds for cash management. The verification findings and opinions are as follows:
1. Basic Situation of Raised Funds
With the approval of the China Securities Regulatory Commission regarding Meikang Biotechnology's stock issuance to specific targets (Zheng Jian Xu Ke [2021] No. 310), the Company issued 39,999,995 ordinary shares (A shares) at a price of RMB 15 per share, raising a total of RMB 599,999,925.00. After deducting issuance expenses of RMB 13,396,226.41 (excluding VAT), the actual net raised funds amounted to RMB 586,603,698.59. The arrival of the raised funds has been verified by Lixin Certified Public Accountants (Special General Partnership) in the "Verification Report" issued on March 18, 2021 (XH Report [2021] No. ZF10146). The raised funds have been deposited into a special account opened for this issuance, and the Company and its subsidiaries implementing the fundraising projects have signed a "Raised Funds Supervision Agreement" with the commercial banks holding the funds and the sponsor to manage the funds in a dedicated manner.
2. Use of Raised Funds and Reasons for Idleness
- Use of Raised Funds
As of April 30, 2026, the investment situation of the raised funds in the fundraising projects is as follows:
| No. | Project Name | Total Investment | Amount of Raised Funds Used | Amount of Raised Funds Already Used | |-----|---------------------------------------|------------------|----------------------------|-------------------------------------| | 1 | R&D and Industrialization of In Vitro Diagnostic Products | 182,150.1 | 170,000.0 | 112,621.5 | | 2 | Information System Upgrade Project | 270,180.0 | 246,603.7 | 86,732.5 | | 3 | Repayment of Bank Loans | 170,000.0 | 170,000.0 | 170,000.0 | | Total | | 622,330.1 | 586,603.7 | 369,935.4 |
Note 1: Includes self-raised funds that have been replaced in advance for the fundraising projects.
Note 2: The shortfall in raised funds will be addressed by the Company’s self-raised funds.